Skip to main content

Crossover Studies with Continuous Variables

  • Chapter
  • First Online:
  • 6107 Accesses

Abstract

Crossover studies with continuous variables are routinely used in clinical drug research: for example, no less than 22% of the double-blind placebo-controlled hypertension trials in 1993 were accordingly designed (Niemeyer et al. 1998). A major advantage of the crossover design is that it eliminates between-subject variability of symptoms. However, problems include the occurrence of carryover effect, sometimes wrongly called treatment-by-period interaction (see also Chap. 17): if the effect of the first period carries on into the next one, then it may influence the response to the latter period. Second, the possibility of time effects due to external factors such as the change of the seasons has to be taken into account in lengthy crossover studies. Third, negative correlations between drug responses, although recently recognized in clinical pharmacology, is an important possibility not considered in the design and analysis of clinical trials so far. Many crossover studies may have a positive correlation-between-drug-response, not only because treatments in a given comparison are frequently from the same class of drugs, but also because one subject is used for comparisons of two treatments. Still, in treatment comparisons of completely different treatments patients may fall into different populations, those who respond better to the test-treatment and those who do so to the reference-treatment. This phenomenon has already lead to treatment protocols based on individualized rather than stepped care (Scheffé 1959). Power analyses for crossover studies with continuous variables so far only accounted for the possibility of approximately zero levels of correlations (Cleophas 1993; Willan and Pater 1986; Freeman 1989; Fleiss 1989; Senn 1994; Grieve 1994). While considering different levels of correlation, we recently demonstrated (Cleophas and Van Lier 1996) that the crossover design with binary variables is a powerful means of determining the efficacy of new drugs in spite of such factors as carryover effects. Crossover trials with continuous variables, however, have not yet been similarly studied.

This is a preview of subscription content, log in via an institution.

Buying options

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   129.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD   109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

References

  • Cleophas TJ (1993) Crossover studies: a modified analysis with more power. Clin Pharmacol Ther 53:515–520

    Article  PubMed  CAS  Google Scholar 

  • Cleophas TJ, Van Lier HH (1996) Clinical trials with binary responses: power analyses. J Clin Pharmacol 36:198–204

    Article  PubMed  CAS  Google Scholar 

  • Fleiss JA (1989) A critique of recent research on the two-treatment crossover design. Control Clin Trials 10:237–241

    Article  PubMed  CAS  Google Scholar 

  • Freeman PR (1989) The performance of the two-stage analysis of two-treatment, two-period crossover trials. Stat Med 8:1421–1432

    Article  PubMed  CAS  Google Scholar 

  • Grieve AP (1994) Bayesian analyses of two-treatment crossover studies. Stat Methods Med Res 3:407–429

    Article  PubMed  CAS  Google Scholar 

  • Grizzle JE (1965) The two-period change-over design and its use in clinical trials. Biometrics 22:469–480

    Google Scholar 

  • Hays WL (1988) Statistics, 4th edn. Holt, Rinehart and Winston, Inc, Fort Worth

    Google Scholar 

  • Niemeyer MG, Zwinderman AH, Cleophas TJ, De Vogel EM (1998) Crossover studies are a better format for comparing equivalent treatments than parallel-group studies. In: Kuhlmann J, Mrozikiewicz A (eds) What should a clinical pharmacologist know to start a clinical trial (phase I and II). Zuckschwerdt Verlag, Munich, pp 40–48

    Google Scholar 

  • Nies AS, Spielberg SP (1996) Individualization of drug therapy. In: Hardman JL et al (eds) Goodman and Gilman’s pharmacological basis of therapeutics. McGraw-Hill, New York, pp 43–63

    Google Scholar 

  • Scheffé H (1959) Mixed models. In: Scheffé H (ed) The analysis of variance. Wiley, New York, pp 261–291

    Google Scholar 

  • Senn S (1994) The AB/BA crossover: past, present and future. Stat Methods Med Res 3:303–324

    Article  PubMed  CAS  Google Scholar 

  • SPSS for Windows. www.SPSS.com. Accessed 15 Dec 2011

  • Willan AR, Pater JL (1986) Carryover and the two-period crossover clinical trial. Biometrics 42:593–599

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

Copyright information

© 2012 Springer Science+Business Media B.V.

About this chapter

Cite this chapter

Cleophas, T.J., Zwinderman, A.H. (2012). Crossover Studies with Continuous Variables. In: Statistics Applied to Clinical Studies. Springer, Dordrecht. https://doi.org/10.1007/978-94-007-2863-9_35

Download citation

Publish with us

Policies and ethics